Tag - CDTX

Developments

Cidara’s workforce restructuring enables focus on clinical development

Cidara Therapeutics (NASDAQ:CDTX) has announced a planned workforce reduction, impacting approximately 30% of the company’s employees, enabling the company to reduce capital needs and concentrate on the clinical...

September 13, 2024

Developments

Cidara, Mundipharma post positive Phase 3 results for rezafungin in candidemia, invasive candidiasis

Cidara Therapeutics (NASDAQ:CDTX) and Mundipharma reported positive topline data from the ReSTORE Phase 3 clinical trial, evaluating the efficacy and safety of its once-weekly antifungal...

December 15, 2021

Developments

Cidara updates Phase 2 rezafungin data

Cidara Therapeutics (NASDAQ:CDTX) reported new data from its Phase 2 STRIVE trial evaluating once-weekly rezafungin for the treatment of candidemia and invasive candidiasis. The trial demonstrated that rezafungin...

October 21, 2020

Feature

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal disease.

June 16, 2020

Developments

Cidara doses first patient in Phase 3 rezafungin trial

Cidara Therapeutics (NASDAQ:CDTX) dosed the first patient in its Phase 3 trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation. The...

May 21, 2020

Tag - CDTX

Cidara’s workforce restructuring enables focus on clinical development

Cidara, Mundipharma post positive Phase 3 results for rezafungin in candidemia, invasive candidiasis

Cidara updates Phase 2 rezafungin data

Cidara platforms targeting prophylactics and treatments for fungal, viral infections

Cidara doses first patient in Phase 3 rezafungin trial

General

More